GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q4 FY22 results · Jan–Mar 2022
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹809.63 crore (down 0.5% from Q4 FY21) and net profit of ₹1,219.05 crore (up 8407.0% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 809.63 | 813.75 | −0.5% | 815.92 | −0.8% |
| Other income | 18.76 | 29.60 | −36.6% | 10.32 | +81.8% |
| Total income | 828.39 | 843.35 | −1.8% | 826.24 | +0.3% |
| Profit before tax | 207.85 | 63.01 | +229.9% | 171.76 | +21.0% |
| Net profit for the period | 1,219.05 | 14.33 | 85x | 150.35 | +710.8% |
| EPS, basic (₹) | 71.96 | 0.85 | 85x | 8.88 | +710.8% |
| Net margin (%) | 150.6 | 1.8 | 18.4 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 791.92 | 807.27 | −1.9% | 807.98 | −2.0% |
| Other income | 18.94 | 29.61 | −36.0% | 10.50 | +80.4% |
| Total income | 810.86 | 836.88 | −3.1% | 818.48 | −0.9% |
| Profit before tax | 206.24 | 60.92 | +238.5% | 170.79 | +20.8% |
| Net profit for the period | 1,217.84 | 12.74 | 96x | 149.63 | +713.9% |
| EPS, basic (₹) | 71.89 | 0.75 | 96x | 8.83 | +714.2% |
| Net margin (%) | 153.8 | 1.6 | 18.5 |
Consolidated
- Filed with BSE
- 17 May 2022, 16:50 IST
- Board meeting
- 16 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 May 2022, 16:50 IST
- Board meeting
- 16 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE